Research programme: antibacterials - Taisho Pharmaceutical/Vernalis

Drug Profile

Research programme: antibacterials - Taisho Pharmaceutical/Vernalis

Alternative Names: Antibiotics - Taisho Pharmaceutical/Vernalis

Latest Information Update: 28 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taisho Pharmaceutical; Vernalis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 28 Apr 2015 Early research in Bacterial infections in United Kingdom, Japan (unspecified route)
  • 07 Apr 2015 Vernalis and Taisho Pharmaceutical agree to co-develop antibacterials for Bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top